CRYOPORT, INC. Net Income (Loss) Attributable to Parent, Diluted
CRYOPORT, INC. (CYRX) reported Net Income (Loss) Attributable to Parent, Diluted of -$10.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-08-06
- CRYOPORT, INC. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was -$10.26M, a 109.60% decline year-over-year.
- CRYOPORT, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was $106.87M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month |
|---|---|---|
| 2026-06-30 | -$10.26M 10-Q · filed 2026-08-06 | -$22.80M 10-Q · filed 2026-08-06 |
| 2025-06-30 | $106.87M 10-Q · filed 2026-08-06 | $92.89M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |